INTRODUCTION
Adenine arabinoside (ara-A,' vidarabine, 9-fl-D-arabinofuranosyladenine) is a clinically effective compound with a relatively wide spectrum of antiviral activity. Although the basis for the antiviral action of ara-A remains unclear, preferential inhibition of a virus-specific DNA polymerase has been the most widely accepted explanation (1) (2) (3) (4) . However, more recent evidence has revealed, in fact, no preferential incorporation into viral DNA (5) . The pharmacologic properties of ara-A therapy in the host may also contribute to toxic manifestations that occur in as many as 44% of certain groups of patients (6) .
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Recent studies indicate that ara-A may interfere with biological methylation by inactivating S-adenosylhomocysteine (Ado-Hcy) hydrolase in vitro (7) . Because other methylation inhibitors possess antiviral activity (8) (9) (10) (11) (12) , and methylation reactions are widely distributed in intermediary metabolism (13) , it is possible that this property could contribute to the antiviral action and systemic toxicity of ara-A. To clarify whether Ado-Hcy hydrolase inactivation occurs during ara-A therapy, and the kinetics of this reaction in vivo, we have examined the alterations of Ado-Hcy hydrolase during low-dose therapy of chronic hepatitis B virus infection.
METHODS
10 patients with chronic hepatitis B virus infection were selected for therapy with antiviral agents as described (14) . Six patients received ara-A alone or in combination with human leukocyte interferon. Four patients received no ara-A during this period of the study and were used as controls. Ara (17) .
Statistical calculations were carried out using the paired or unpaired Student's t test.
before, during, and after therapy. Pretreatment bloods from these patients, as well as blood from untreated patients, were used for controls. Ado-Hcy hydrolase activity in washed erythrocytes in controls was compared with enzyme activity at the end of a 12-h infusion of ara-A. These data are shown in Fig. 1 . All 17 control samples fell within the previously established normal range of activity for this enzyme (3.9-9.8 nmol/h per mg). A decrease in enzyme activity was seen in all patients receiving ara-A. 37 samples from treated patients were analyzed with a mean of 0.2±0.2(SD) nmol/h per mg (P < 0.001).
Erythrocyte purine nucleoside phosphorylase was assayed on 17 of the 37 samples as a form of internal control. Activity of this enzyme in control bloods and postinfusion bloods was within the normal range (1,014.6 to 3,318.2 nmol/h per mg) with a mean of 1,861.5 ±253.5 (SD) nmol/h per mg and 2,164.6 ±583.7 (SD) nmol/h per mg, respectively (data not shown).
To distinguish whether inactivation of Ado-Hcy hydrolase resulted from ara-A or its major metabolite, ara-hypoxanthine (ara-Hj), hemolysate from an untreated subject was analyzed for this enzyme activity after addition of these compounds to whole blood before separation of the erythrocytes. No inhibition was The time-course of Ado-Hcy hydrolase inactivation was examined in cells from two patients (Fig. 2) . Mean erythocyte Ado-Hcy hydrolase activity was 8.0 nmol/ h per mg before therapy. 4 h after the start of the drug infusion, mean enzyme activity had decreased to 0.6 nmol/h per mg or 8% of pretreatment levels. At the end of the first 12-h infusion, mean enzyme activity had decreased to 0.2 nmol/h per mg, or 2% of pretreatment values. A small rise in activity occurred each day during the infusion-free period with repeat suppression at the end of each subsequent infusion. After cessation of the 10-d course of therapy, enzyme levels slowly increased. Levels reached the normal range on day 9 post withdrawal of ara-A, but remained lower than pretreatment values for 30 d posttherapy. During the same period mononuclear cell Ado-Hcy hydrolase ranged from a pretreatment value of 244.0 nmol/h per mg to a low value of 5.2 nmol/h per mg (Fig. 3) . However, rises and falls were seen in enzyme activity throughout the treatment period.
Circulating lymphocyte counts were measured in five patients analyzed for Ado-Hcy hydrolase activity. Fig. 4 displays these data. Pretreatment circulating lymphocytes were 1,988 ± 823 (SD) per mm3. These counts were decreased to 599±296(SD) per mm3 or 34.4 ± 23.9% (SD) of pretreatment values after 7-10 d of therapy. This decrease was significant (P < 0.01 by paired t test) and was seen in all five patients studied. DISCUSSION A diminution of Ado-Hcy hydrolase occurs in erythrocytes and lymphocytes of patients receiving ara-A. The alteration in erythrocytes continues for many days after cessation of therapy, beyond the period of detectability of ara-A or ara-H., its major metabolite. In addition, this inactivation is the result of therapy with ara-A, rather than the effect of ara-H.. Irreversible inactivation of Ado-Hcy hydrolase by ara-A (7) is the most likely explanation for our observations and a similar change in a single patient after completion of therapy (18) . Ado-Hcy that follows enzyme inactivation inhibits cellular transmethylation reactions and leads to toxicity toward B lymphoblasts, T lymphoblasts, and macrophages (19) (20) (21) . Severe immune dysfunction with lymphocytopenia and neurological abnormalities occurs in adenosine deaminase deficiency (22, 23) Hcy hydrolase in erythrocytes (15, 24) . However, the exact contribution of the Ado-Hcy hydrolase deficiency to the disorders associated with adenosine deaminase deficiency remains unclear.
It is possible that inactivation of Ado-Hcy hydrolase could mediate certain toxic manifestations of ara-A therapy. Lymphocyte counts were diminished in 98% of all treatment courses, reaching a mean nadir of 48% of pretreatment lymphocyte counts by day 5 of therapy (6) . We have also demonstrated similar findings in a subgroup of five patients studied both for enzyme activity and lymphocyte effects. Apparent lympholytic properties of ara-A (25) could be mediated by inactivation of Ado-Hcy hydrolase. While adenine arabinoside triphosphate accumulation has been previously associated with ara-A cytotoxicity in cultured T lymphoblasts (26) , it is possible that adenine arabi- End of therapy FIGURE 4 Circulating lymphocyte counts in five patients undergoing therapy with ara-A in whom erythrocyte AdoHcy hydrolase activity was measured. Pretreatment and posttreatment lymphocyte counts are compared in each patient. The patients whose mononuclear Ado-Hcy hydrolase activity were measured are marked separately (-). noside triphosphate accumulation is not a factor in peripheral lymphocytes. The latter biochemically resemble B lymphoblasts (27) , which accumulate little or no adenine arabinoside triphosphate (28) and which are 10-fold less sensitive to the toxic properties of ara-A than are cultured T lymphoblasts (26) .
Ado-Hcy hydrolase inactivation during ara-A therapy may have clinical relevance. Lymphocytotoxicity of this compound could be mediated in part through this mechanism. Secondly, inhibition of transmethylation reactions could have significance as a mechanism of antiviral action for ara-A, especially because inhibition of transmethylation reactions has established antiviral properties (8) (9) (10) (11) (12) . Whereas no specific data is presented here to implicate this pathway as the antiviral mechanism, the in vivo potential for transmethylation inhibition is provided by Ado-Hcy inactivation. Further investigation of the mechanisms of action and toxicity of ara-A should be undertaken.
